The UK approved it in November, the (US)FDA approved it (EUA) in December, 2021. Australia's contribution seems to be limited to buying the stuff.
Developed at Emory University in Atlanta, GA, funded by the Defense Threat Reduction agency. Abandoned by Emory due to "mutagenicity" risks. Licensed to Ridgeback Biotherapeutics who partnered with Merck to bring it to market.
Here's the best part: In September 2021, Merck signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) that allows MPP to sublicense molnupiravir and supply the COVID-19 oral medication to 105 low- and middle-income countries. The cost of the initial purchase made by the US government was about $712 per course of treatment, while treatment with generics in developing countries can cost as little as $20.
Our (US) tax dollars paid for its development and for that, we get to pay 35x as much as other countries pay for generics.
https://en.wikipedia.org/wiki/Molnupiravir